Logo image
Back
Spectrum of dominant Charcot-Marie-Tooth disease due to SLC12A6 variants
Journal article   Open access   Peer reviewed

Spectrum of dominant Charcot-Marie-Tooth disease due to SLC12A6 variants

Christopher J Record, Tiffany Grider, Adriana P Rebelo, Christian Laurini, Mariola Skorupinska, Matt C Danzi, Roy Poh, Pedro J Tomaselli, Rodrigo S Frezatti, Natalia Dominik, …
Journal of neurology, neurosurgery and psychiatry, Vol.97(4), pp.283-292
04/2026
DOI: 10.1136/jnnp-2025-336643
PMCID: PMC13018852
PMID: 41500801
url
https://doi.org/10.1136/jnnp-2025-336643View
Published (Version of record) Open Access

Abstract

BackgroundHeterozygous variants in SLC12A6 have recently been shown to cause dominant Charcot-Marie-Tooth disease (CMT). We aim to characterise the phenotype of patients with previously reported and novel heterozygous variants in the gene and understand any genotype-phenotype correlation.MethodsPatients were clinically and genetically assessed in sites from Europe, Australia, Brazil and the USA. All patients underwent whole exome or whole genome sequencing. Variants were classified using American College of Medical Genetics and Genomics criteria.ResultsTwenty-three individuals from 13 families carried nine variants classified either as pathogenic/likely pathogenic or variants of uncertain significance segregating in multiple family members, including five novel variants. Forty-eight percent (11/23) were male with a mean age of disease onset of 15.7 years (range 1–45 years). Clinical phenotype varied dramatically with genotype; Arg207His and Ser647Pro caused a severe childhood-onset, sensory and motor, conduction-slowing neuropathy, whereas Gly552Asp caused a mild, adult-onset, sensory-predominant neuropathy, Thr991Ala an infantile-onset motor neuropathy, and the Met282Lys/Gly286Cys locus a complex, axonal neuropathy.ConclusionsHeterozygous variants in SLC12A6 can cause CMT of all clinical phenotypes, severity and age of onset, depending on the genotype. Such phenotypic diversity has not been described for any other CMT gene, and more work is needed to understand disease mechanisms to guide future therapeutic options.
 Genetics CHANNELS HMSN (CHARCOT-MARIE-TOOTH) Neuromuscular NEUROPATHY

Details

Metrics

5 Record Views
Logo image